Paul Rubin

Company: BioAge Labs

Job title: Chief Medical Officer

Seminars:

Investigating Combination Therapy with an Oral Apelin Receptor Agonist to Increase the Efficacy of Incretin Drugs for Weight Loss 5:15 pm

Focusing on strategies for combining oral GLP-1s with complementary mechanisms to achieve injectable-like weight loss with improved body composition Reviewing pre-clinical data showing that azelaprag, a first-in-class apelin receptor agonist that improved muscle metabolism in older people in a Ph1b study, fully restores body weight, body composition, and muscle function to that of lean controls…Read more

day: Conference Day One